Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy: Sungjin Kim, Jeonghyo Lee, Jin-Haeng Chung; Cancer Res Treat. 2025;57(2):401-411. Published online September 9, 2024; DOI: https://doi.org/10.4143/crt.2024.670

Abstract PDF Supplementary Material PubReader ePub: Purpose
Major pathologic response (MPR), defined as ≤ 10% of residual viable tumor (VT), is a prognostic factor in non–small cell lung cancer (NSCLC) after neoadjuvant therapy. This study evaluated interobserver reproducibility in assessing MPR, compared area-weighted and unweighted VT (%) calculation, and determined optimal VT (%) cutoffs across histologic subtypes for survival prediction.
Materials and Methods
This retrospective study included 108 patients with NSCLC who underwent surgical resection after neoadjuvant chemotherapy or chemoradiation at Seoul National University Bundang Hospital between 2009-2018. Three observers with varying expertise independently assessed tumor bed and VT (%) based on digital whole-slide images.
Results
Reproducibility in tumor bed delineation was reduced in squamous cell carcinoma (SqCC) with smaller tumor bed, although overall concordance was high (Dice coefficient, 0.96; intersection-over-union score, 0.92). Excellent agreement was achieved for VT (%) (intraclass correlation coefficient=0.959) and MPR using 10% cutoff (Fleiss’ kappa=0.911). Shifting between area-weighted and unweighted VT (%) showed only one case differing in MPR status out of 81 cases. The optimal cutoff was 10% for both adenocarcinoma (ADC) and SqCC. MPR+ was observed in 18 patients (17%), with SqCC showing higher MPR+ rates (p=0.044), lower VT (%) (p < 0.001), and better event-free survival (p=0.015) than ADC. MPR+ significantly improved overall survival (p=0.023), event-free survival (p=0.001), and lung cancer-specific survival (p=0.012).
Conclusion
While MPR assessment demonstrated robust reproducibility with minimal impact from the tumor bed, attention is warranted when evaluating smaller tumor beds in SqCC. A 10% cutoff reliably predicted survival across histologic subtypes with higher interobserver reproducibility.

1,048 View
95 Download

Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome: Walid Shaib, Kavya Krishna, Sungjin Kim, Michael Goodman, Jonathan Rock, Zhengjia Chen, Edith Brutcher, Charles III Staley, Shishir K. Maithel, Samih Abdel-Missih, Bassel F. El-Rayes, Tanios Bekaii-Saab; Cancer Res Treat. 2016;48(2):596-604. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2015.029

Abstract PDF PubReader ePub

Purpose
Appendiceal tumors are a heterogeneous group of diseases that include typical neuroendocrine tumors (TNET), goblet cell carcinoids (GCC), and atypical GCC. Atypical GCC are classified into signet-ring cell cancers (SRCC) and poorly differentiated appendiceal adenocarcinoids. The prognosis and management of these diseases is unclear because there are no prospective studies. The aim of this study is to assess the characteristics and outcome of appendiceal TNET, GCC, and SRCC patients.
Materials and Methods
Appendiceal TNET, GCC, and SRCC patients diagnosed between 1973 and 2011 were identified in the Surveillance Epidemiology and End Results (SEER) database. Demographics, type of surgery, and clinicopathologic characteristics were collected. Survival functions were estimated by the Kaplan-Meier method, and log-rank test was used to assess the difference in overall survival (OS) among the three histologies.
Results
The SEER database yielded 1,021 TNET patients, 1,582 with GCC, and 534 SRCC patients. TNET presented at a younger age (p < 0.001). Patients with SRCC presented with advanced stage disease (p < 0.001). The median OS (mOS) for GCC and TNET patients was not reached; mOS for SRCC was 24 months. Multivariate analysis stratified for stage revealed significantly longer survival for TNET and GCC than SRCC (p < 0.001).
Conclusion
This is the largest report to date for appendiceal neuroendocrine tumor patients, suggesting a spectrum of diseases with different characteristics and outcomes. In this report, we present a treatment approach for this complex spectrum of disease, based on the experience of Ohio State and Emory Universities investigators.

Citations

Citations to this article as recorded by

Postoperative 68Ga‐DOTATATE positron emission tomography has a low yield in incidental appendiceal neuroendocrine tumours
Emilie Pauvert, George Larcos
ANZ Journal of Surgery.2024; 94(12): 2185. CrossRef
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis
Claudio Ricci, Davide Campana, Carlo Ingaldi, Giuseppe Lamberti, Laura Alberici, Valentina Tateo, Giovanni Castagna, Gianluca Ricco, Fulvio Calderaro, Deborah Malvi, Francesca Rosini, Riccardo Casadei
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Appendixneoplasien
Safak Gül-Klein, Alexander Arnold, Christian Oberender, Matylda Zofia Kuzinska, Miguel Enrique Alberto Vilchez, Martina T. Mogl, Beate Rau
coloproctology.2023; 45(2): 139. CrossRef
Collision Tumor of the Appendix
Álvaro Morillo Cox, Tatiana Fernandez Trokhimtchouk, Luis F Flores, Diego Viteri, Olmedo Mancero, Estefanie S Otanez
Cureus.2023;[Epub] CrossRef
The Promise of Epigenetics Research in the Treatment of Appendiceal Neoplasms
Luisa Ladel, Wan Ying Tan, Thanushiya Jeyakanthan, Bethsebie Sailo, Anup Sharma, Nita Ahuja
Cells.2023; 12(15): 1962. CrossRef
Incidental Detection and Management of a Neuroendocrine Carcinoid Tumor of the Appendix in a Young Male Patient
Anjani H Turaga
Cureus.2023;[Epub] CrossRef
An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Frederic Mercier, Guillaume Passot, Pierre‐Emmanuel Bonnot, Peter Cashin, Wim Ceelen, Evelyne Decullier, Laurent Villeneuve, Thomas Walter, Edward A. Levine, Olivier Glehen
World Journal of Surgery.2022; 46(6): 1336. CrossRef
New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Feng Yin, Zi-Hao Wu, Jin-Ping Lai
World Journal of Gastroenterology.2022; 28(17): 1751. CrossRef
Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry
Kieran Palmer, Scott Weerasuriya, Kandiah Chandrakumaran, Brian Rous, Benjamin E. White, Sangeeta Paisey, Rajaventhan Srirajaskanthan, John K. Ramage
Frontiers in Oncology.2022;[Epub] CrossRef
Current Management of Appendiceal Neoplasms
Richard S. Hoehn, Caroline J. Rieser, M. Haroon Choudry, Nelya Melnitchouk, Jaclyn Hechtman, Nathan Bahary
American Society of Clinical Oncology Educational Book.2021; (41): 118. CrossRef
Appendiceal goblet cell carcinomas have poor survival despite completion surgery
Edward Alabraba, David Mark Pritchard, Rebecca Griffin, Rafael Diaz-Nieto, Melissa Banks, Daniel James Cuthbertson, Stephen Fenwick
Endocrine.2021; 73(3): 734. CrossRef
Primary adenocarcinoma of the appendix presenting with fresh bleeding per rectum: A case report
Baijaeek Sain, Arnab Gupta, Samir Bhattacharya, Radha Raman Mondal, Sudip Haldar, Shravasti Roy
International Journal of Surgery Case Reports.2021; 86: 106285. CrossRef
Omission of Right Hemicolectomy May be Safe for Some Appendiceal Goblet Cell Adenocarcinomas: A Survival Analysis of the National Cancer Database
Stacy J. Kowalsky, Ibrahim Nassour, Samer AlMasri, Alessandro Paniccia, Amer H. Zureikat, Haroon A. Choudry, James F. Pingpank
Annals of Surgical Oncology.2021; 28(13): 8916. CrossRef
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Score–Matched Analysis of Centers in the Netherlands and Belgium
Nina R. Sluiter, Jarmila D. van der Bilt, Dorothée M.R. Croll, Menno R. Vriens, Ignace H.J.T. de Hingh, Patrick Hemmer, Arend G.J. Aalbers, Andreas J.A. Bremers, Wim Ceelen, Andre D’Hoore, Linda J. Schoonmade, Veerle Coupé, Henk Verheul, Geert Kazemier, J
Clinical Colorectal Cancer.2020; 19(3): e87. CrossRef
Neuroendocrine tumors of the appendix
V. S. Trifanov, O. I. Kit, E. N. Kolesnikov, A. V. Snezhko, S. V. Sanamyanz, M. A. Kozhushko, M. Yu. Mesheryakova
Experimental and Clinical Gastroenterology.2020; 174(5): 82. CrossRef
Survival Profile and Prognostic Factors for Appendiceal Mixed Neuroendocrine Non-neuroendocrine Neoplasms: A SEER Population-Based Study
Mengzhen Zheng, Tong Li, Yan Li, Tengfei Zhang, Lianfeng Zhang, Wang Ma, Lin Zhou
Frontiers in Oncology.2020;[Epub] CrossRef
Appendiceal neoplasm risk associated with complicated acute appendicitis—a population based study
Elina Lietzén, Juha M. Grönroos, Jukka-Pekka Mecklin, Ari Leppäniemi, Pia Nordström, Tero Rautio, Tuomo Rantanen, Juhani Sand, Hannu Paajanen, Anne Kaljonen, Paulina Salminen
International Journal of Colorectal Disease.2019; 34(1): 39. CrossRef
Hypofractionated Stereotactic Radiation Therapy for Metastatic Adenocarcinoma ex Goblet Cell Carcinoid of the Appendix: Case Report and Literature Review
Joseph W. Clyde, Alan W. Katz
Case Reports in Oncology.2019; 12(3): 807. CrossRef
Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature
Gregory Gilmore, Kristin Jensen, Shreyas Saligram, Thomas P. Sachdev, Subramanyeswara R. Arekapudi
Journal of Medical Case Reports.2018;[Epub] CrossRef
Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine
Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel, Beata Kotowicz
Endocrine Connections.2018; 7(6): 803. CrossRef
Perforated Goblet Cell Carcinoid Tumors of the Appendix: Navigating the Management Conundrum
Suman B. Koganti, Brian F. Gilchrist, Tresara C. Bell
International Surgery.2017; 102(3-4): 131. CrossRef
Appendiceal neuroendocrine neoplasms: diagnosis and management
Krystallenia I Alexandraki, Gregory A Kaltsas, Simona Grozinsky-Glasberg, Eleftherios Chatzellis, Ashley B Grossman
Endocrine-Related Cancer.2016; 23(1): R27. CrossRef
Goblet cell carcinoids of the appendix: Tumor biology, mutations and management strategies
Santosh Shenoy
World Journal of Gastrointestinal Surgery.2016; 8(10): 660. CrossRef

15,012 View
173 Download
29 Web of Science
23 Crossref

First
Prev
Page of 1
Next
Last

Search